Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · IEX Real-Time Price · USD
7.47
-0.48 (-6.04%)
At close: Jul 2, 2024, 4:00 PM
8.04
+0.57 (7.63%)
After-hours: Jul 2, 2024, 7:49 PM EDT

Verrica Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2016
Revenue
5.129.031200
Upgrade
Revenue Growth (YoY)
-43.27%-24.73%---
Upgrade
Cost of Revenue
0.750.73000
Upgrade
Gross Profit
4.388.311200
Upgrade
Selling, General & Admin
47.3117.4126.9824.5114.64
Upgrade
Research & Development
20.312.215.9315.6715.44
Upgrade
Other Operating Expenses
2.540000
Upgrade
Operating Expenses
70.1429.642.9140.1830.08
Upgrade
Operating Income
-65.76-21.3-30.91-40.18-30.08
Upgrade
Interest Expense / Income
3.962.174.33.030
Upgrade
Other Expense / Income
-2.731.02-0.12-0.52-1.87
Upgrade
Pretax Income
-67-24.49-35.08-42.69-28.21
Upgrade
Net Income
-67-24.49-35.08-42.69-28.21
Upgrade
Shares Outstanding (Basic)
4534272525
Upgrade
Shares Outstanding (Diluted)
4534272525
Upgrade
Shares Change
32.72%26.32%8.20%0.39%69.80%
Upgrade
EPS (Basic)
-1.48-0.72-1.30-1.71-1.13
Upgrade
EPS (Diluted)
-1.48-0.72-1.30-1.71-1.13
Upgrade
Free Cash Flow
-38.94-18.95-28.47-31.68-28.09
Upgrade
Free Cash Flow Per Share
-0.86-0.56-1.05-1.27-1.13
Upgrade
Gross Margin
85.44%91.97%100.00%--
Upgrade
Operating Margin
-1283.35%-235.78%-257.57%--
Upgrade
Profit Margin
-1307.47%-271.11%-292.33%--
Upgrade
Free Cash Flow Margin
-759.93%-209.83%-237.21%--
Upgrade
EBITDA
-62.2-21.6-30.31-39.43-27.95
Upgrade
EBITDA Margin
-1213.84%-239.12%-252.61%--
Upgrade
Depreciation & Amortization
0.840.720.470.230.26
Upgrade
EBIT
-63.03-22.32-30.79-39.66-28.21
Upgrade
EBIT Margin
-1230.15%-247.07%-256.54%--
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).